Case Report: Rituximab Combined with Plasma Exchange Treatment for Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy and Non-cirrhotic Portal Hypertension

Overview

Journal Front Immunol

Date 2025 Jan 20

PMID 39830503

Authors

Jinmei Huang

Wei Fan

Xuyan Chen

Shufan Wu

Zhigao Dong

Yi Zhang

Yiwan Lin

Pingping Xiao

Affiliations

Soon will be listed here.

Abstract

Introduction: Systemic lupus erythematosus (SLE) complicated by thrombotic microangiopathy (TMA) and non-cirrhotic portal hypertension (NCPH) is rare. We present a case of a female patient with SLE who developed TMA and NCPH and responded positively to rituximab and plasma exchange treatment.

Case Description: A 53-year-old woman was admitted with 6 h of confusion. Upon admission, she was diagnosed with SLE complicated by lupus encephalopathy, blood system impairment, cardiomyopathy, and nephritis. Initial treatment with high-dose methylprednisolone, immunoglobulin shock therapy, and tacrolimus (1 mg, twice daily) improved her symptoms and laboratory indicators. However, after a pulmonary infection and infection with the 2019 novel coronavirus, the patient's condition deteriorated further. She experienced confusion and a delayed response. Hemoglobin levels and platelet counts decreased, lactate dehydrogenase and creatinine levels increased, and the percentage of peripheral schistocytes was approximately 6.5%. Abdominal ultrasonography revealed a substantial amount of ascites, diffuse liver lesions, splenomegaly, and splenic varices. Enhanced computed tomography revealed diffuse liver disease along the portal veins, intrahepatic lymphatic dilatation, esophageal and gastric varices, a splenorenal vein shunt, and splenomegaly. The patient was negative for hepatitis virus, autoimmune liver disease antibodies, ceruloplasmin, and tumor markers. Therefore, SLE complicated by TMA and NCPH was considered. She was treated with high-dose methylprednisolone (500 mg) for 3 days and immunoglobulin (0.4 g/kg/day) for 5 days, followed by rituximab (500 mg) for suppressive immunotherapy combined with plasma exchange (seven times), low-molecular-weight heparin (5,000 U every 12 h) for anticoagulation, and a diuretic. The patient's symptoms and laboratory indicators improved.

Conclusion: This case suggests that a combination of rituximab, plasma exchange, anticoagulation, and diuretics may be an effective treatment for patients with SLE complicated by TMA and NCPH.

References

Kotzen E, Roy S, Jain K . Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019; 26(5):376-386. PMC: 8958719. DOI: 10.1053/j.ackd.2019.08.012. View

Kamiya K, Kurasawa K, Arai S, Maezawa R, Hanaoka R, Kumano K . Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol. 2009; 20(1):81-5. DOI: 10.1007/s10165-009-0231-8. View

George J . The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv. 2018; 2(12):1510-1516. PMC: 6020802. DOI: 10.1182/bloodadvances.2018018432. View

Del Rio Zanatta H, Zambrano Zambrano A, Belmont Nava P, Lizbeth Puntos Guizar C, Martinez Salazar J . Comprehensive Evaluation of Neuropsychiatric and Mucocutaneous Manifestations in the Diagnosis of Systemic Lupus Erythematosus: A Complete Clinical Approach to a Case. Cureus. 2023; 15(10):e47380. PMC: 10657573. DOI: 10.7759/cureus.47380. View

Brocklebank V, Wood K, Kavanagh D . Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2017; 13(2):300-317. PMC: 5967417. DOI: 10.2215/CJN.00620117. View

Imabayashi K, Nakano K, Iwata S, Tanaka Y . A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. Mod Rheumatol Case Rep. 2021; 5(2):285-291. DOI: 10.1080/24725625.2021.1904607. View

Yang Q, He Y, Peng C, Qing Y, He Q, Zhou J . Systemic lupus erythematosus complicated by noncirrhotic portal hypertension: A case report and review of literature. World J Clin Cases. 2018; 6(13):688-693. PMC: 6232573. DOI: 10.12998/wjcc.v6.i13.688. View

Bensalek F, Joulal H, Yousfi J, Zahlane M, Benjilali L, Essaadouni L . Autoimmune Myelofibrosis Revealing a Systemic Lupus Erythematosus. Eur J Case Rep Intern Med. 2024; 11(6):004511. PMC: 11152231. DOI: 10.12890/2024_004511. View

Torun E, Erciyestepe M, Yalcinkaya Y, Gul A, Inanc M, Ocal L . A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt. Clin Med Insights Case Rep. 2022; 15:11795476221100595. PMC: 9121445. DOI: 10.1177/11795476221100595. View

10.

Limal N, Cacoub P, Sene D, Guichard I, Piette J . Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2007; 17(1):69-71. DOI: 10.1177/0961203307083479. View

11.

Ineichen B, Moridi T, Granberg T, Piehl F . Rituximab treatment for multiple sclerosis. Mult Scler. 2019; 26(2):137-152. DOI: 10.1177/1352458519858604. View

12.

Fabritiis M, Angelini M, Fabbrizio B, Cenacchi G, Americo C, Cristino S . Renal Thrombotic Microangiopathy in Concurrent COVID-19 Vaccination and Infection. Pathogens. 2021; 10(8). PMC: 8400339. DOI: 10.3390/pathogens10081045. View

13.

Chen R, Li X, Lin Q, Tang H, Cui N, Jiang L . Pathological evaluation of renal complications in children following allogeneic hematopoietic stem cell transplantation: a retrospective cohort study. BMC Pediatr. 2023; 23(1):186. PMC: 10120150. DOI: 10.1186/s12887-023-03996-1. View

14.

Lansigan F, Isufi I, Tagoe C . Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology (Oxford). 2010; 50(5):824-9. DOI: 10.1093/rheumatology/keq395. View

15.

Horita T, Tsutsumi A, Takeda T, Yasuda S, Takeuchi R, Amasaki Y . Significance of magnetic resonance imaging in the diagnosis of nodular regenerative hyperplasia of the liver complicated with systemic lupus erythematosus: a case report and review of the literature. Lupus. 2002; 11(3):193-6. DOI: 10.1191/0961203302lu164cr. View

16.

Inagaki H, Nonami T, Kawagoe T, Miwa T, Hosono J, Kurokawa T . Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol. 2001; 35(3):235-9. DOI: 10.1007/s005350050336. View

17.

Sun F, Wang X, Wu W, Wang K, Chen Z, Li T . TMA secondary to SLE: rituximab improves overall but not renal survival. Clin Rheumatol. 2017; 37(1):213-218. DOI: 10.1007/s10067-017-3793-4. View

18.

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

19.

Zhou Y, Zhao J, Cao X, Zheng K, Wu Q, Zeng X . [The 476th case: skin rash, edema, thrombocytopenia and anemia]. Zhonghua Nei Ke Za Zhi. 2020; 59(3):250-252. DOI: 10.3760/cma.j.issn.0578-1426.2020.03.019. View

20.

Letchumanan P, Ng H, Lee L, Thumboo J . A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009; 48(4):399-403. DOI: 10.1093/rheumatology/ken510. View